134 related articles for article (PubMed ID: 34479190)
1. Targeting of cyclin-dependent kinases in atypical teratoid rhabdoid tumors with multikinase inhibitor TG02.
Ding AS; Huq S; Casaos J; Raj D; Morales M; Zhao T; Kim T; Srivastava S; Pant A; Serra R; Gorelick NL; Brem H; Tyler B
J Neurosurg Pediatr; 2021 Sep; 28(6):734-743. PubMed ID: 34479190
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
5. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.
Casaos J; Huq S; Lott T; Felder R; Choi J; Gorelick N; Peters M; Xia Y; Maxwell R; Zhao T; Ji C; Simon T; Sesen J; Scotland SJ; Kast RE; Rubens J; Raabe E; Eberhart CG; Jackson EM; Brem H; Tyler B; Skuli N
Oncotarget; 2018 Jan; 9(8):8054-8067. PubMed ID: 29487714
[TBL] [Abstract][Full Text] [Related]
7. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
8. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup.
Johann PD; Bens S; Oyen F; Wagener R; Giannini C; Perry A; Raisanen JM; Reis GF; Nobusawa S; Arita K; Felsberg J; Reifenberger G; Agaimy A; Buslei R; Capper D; Pfister SM; Schneppenheim R; Siebert R; Frühwald MC; Paulus W; Kool M; Hasselblatt M
Am J Surg Pathol; 2018 Apr; 42(4):506-511. PubMed ID: 29324471
[TBL] [Abstract][Full Text] [Related]
9. Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets.
Hua T; Zeng Z; Chen J; Xue Y; Li Y; Sang Q
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954348
[TBL] [Abstract][Full Text] [Related]
10. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
11. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
[TBL] [Abstract][Full Text] [Related]
12. Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.
Ho B; Johann PD; Grabovska Y; De Dieu Andrianteranagna MJ; Yao F; Frühwald M; Hasselblatt M; Bourdeaut F; Williamson D; Huang A; Kool M
Neuro Oncol; 2020 May; 22(5):613-624. PubMed ID: 31889194
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors.
Tran HM; Wu KS; Sung SY; Changou CA; Hsieh TH; Liu YR; Liu YL; Tsai ML; Lee HL; Hsieh KL; Huang WC; Liang ML; Chen HH; Lee YY; Lin SC; Ho DM; Chang FC; Chao ME; Chen W; Chu SS; Yu AL; Yen Y; Chang CC; Wong TT
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32235770
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid.
Hoffman MM; Zylla JS; Bhattacharya S; Calar K; Hartman TW; Bhardwaj RD; Miskimins WK; de la Puente P; Gnimpieba EZ; Messerli SM
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32210076
[TBL] [Abstract][Full Text] [Related]
15. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
Le Rhun E; von Achenbach C; Lohmann B; Silginer M; Schneider H; Meetze K; Szabo E; Weller M
Int J Cancer; 2019 Jul; 145(1):242-253. PubMed ID: 30549269
[TBL] [Abstract][Full Text] [Related]
16. Pediatric primary spinal atypical teratoid rhabdoid tumor: a case series and review of the literature.
Li D; Heiferman DM; Syed HR; Santos JG; Bowman RM; DiPatri AJ; Tomita T; Wadhwani NR; Alden TD
J Neurosurg Pediatr; 2019 Jul; 24(3):267-283. PubMed ID: 31299639
[TBL] [Abstract][Full Text] [Related]
17. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.
Frühwald MC; Hasselblatt M; Nemes K; Bens S; Steinbügl M; Johann PD; Kerl K; Hauser P; Quiroga E; Solano-Paez P; Biassoni V; Gil-da-Costa MJ; Perek-Polnik M; van de Wetering M; Sumerauer D; Pears J; Stabell N; Holm S; Hengartner H; Gerber NU; Grotzer M; Boos J; Ebinger M; Tippelt S; Paulus W; Furtwängler R; Hernáiz-Driever P; Reinhard H; Rutkowski S; Schlegel PG; Schmid I; Kortmann RD; Timmermann B; Warmuth-Metz M; Kordes U; Gerss J; Nysom K; Schneppenheim R; Siebert R; Kool M; Graf N
Neuro Oncol; 2020 Jul; 22(7):1006-1017. PubMed ID: 31883020
[TBL] [Abstract][Full Text] [Related]
18. Atypical teratoid rhabdoid tumor: current therapy and future directions.
Ginn KF; Gajjar A
Front Oncol; 2012; 2():114. PubMed ID: 22988546
[TBL] [Abstract][Full Text] [Related]
19. The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth.
Alimova I; Murdock G; Pierce A; Wang D; Madhavan K; Brunt B; Venkataraman S; Vibhakar R
Neurooncol Adv; 2023; 5(1):vdad010. PubMed ID: 36915612
[TBL] [Abstract][Full Text] [Related]
20. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
